Exosome Diagnostics, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Exosome Diagnostics, Inc.
Supporting ‘n of 1’ gene therapy development, the playbook from a Foundation for the National Institutes of Health-backed consortium aims to help investigators who are not traditional product sponsors prepare for meetings with US FDA and IND submissions.
2023 saw a number of gene therapy companies go to the wall, but those that can combine clinical significance and commercial success can build sustainable businesses.
Novartis revealed detailed terms and a 4 October spin-off date for Sandoz’s standalone debut. Also, MIRA launched a small IPO, but two firms plan to go public in SPAC mergers. Also, Mirati’s $345m offering leads follow-ons offerings and Sangon Biotech raised $290m in venture capital.
The US biotech’s TSHA-102 has shown surprisingly early signs of functional improvement in a single patient treated in its Phase I/II Rett syndrome trial, promoting a major stock surge supported by the news of a $150 private placement and regulatory updates.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.